Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Biotech
Cytokinetics’ ph. 3 cardio win sends stock soaring
Aficamten bested a standard-of-care beta blocker in a phase 3 heart disease test, bolstering the asset's blockbuster expectations.
Darren Incorvaia
Sep 2, 2025 2:05pm
Rocket's gene therapy sets new efficacy bar in ph. 1 heart study
May 16, 2025 10:36am
Edgewise claims heart pressure reductions for Camzyos rival
Apr 2, 2025 8:45am
BMS' MyoKardia scraps heart muscle pact with Fulcrum
Mar 5, 2025 5:30am
BridgeBio touts extension study data for ATTR-CM drug acoramidis
Nov 18, 2024 3:38pm
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
Nov 18, 2024 7:40am
